• In Q2 2026, Agilent Technologies reported results that exceeded expectations and raised its fiscal 2026 guidance, prompting analysts to reiterate a “Moderate Buy” consensus as of August 2026.
• This combination of stronger-than-anticipated performance and higher guidance has reinforced confidence in Agilent’s ability to execute on its life sciences and diagnostics-focused business model.
• Next, we’ll examine how Agilent’s upgraded 2026 guidance affects its investment narrative, particularly around expected earnings growth and margin expansion.

Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.

Agilent Technologies Investment Narrative Recap

To own Agilent, you need to believe its life sciences and diagnostics tools can keep attracting steady customer demand, even as funding cycles and capital budgets ebb and flow. The Q2 2026 beat and guidance raise support the near term earnings and margin story, but they do not remove the key risk that higher tariffs and ongoing supply chain complexity could still pressure profitability if mitigation falls short.

The full year 2026 revenue guidance increase to US$7.3 billion to US$7.5 billion, with mid single digit growth, sits at the center of this story. It connects the recent share price strength with the core catalyst of execution on product launches and end market demand, while putting a brighter spotlight on whether Agilent can offset tariff driven cost headwinds and protect margins if trade and logistics pressures persist.

Yet behind the upgraded outlook, investors should also be aware that tariff driven supply chain risks could still...

Agilent Technologies' narrative projects $8.8 billion revenue and $2.1 billion earnings by 2029. This requires 6.7% yearly revenue growth and about a $0.7 billion earnings increase from $1.4 billion today.

Uncover how Agilent Technologies' forecasts yield a $161.00 fair value, in line with its current price.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community span roughly US$150.54 to US$177.51 per share, showing a wide spread of views. Set against Agilent’s raised 2026 guidance, this range underlines how differently investors may weigh potential earnings growth against ongoing tariff and supply chain pressures.

Explore 4 other fair value estimates on Agilent Technologies - why the stock might be worth as much as 12% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Agilent Technologies research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Agilent Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Agilent Technologies' overall financial health at a glance.

Searching For A Fresh Perspective?

Our top stock finds are flying under the radar-for now. Get in early:

• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.